Evidence map›Paper›PMID 40586426›Full record

ArticleAnnals of medicine2025

Diagnostic pathway for cardiac amyloidosis from the healthcare professional's perspective: results from the French DIAM-ATTR survey.

Silvia Oghina, Damien Legallois, Fabien Hyafil, Walid Amara, Emmanuel Andrès, Thomas Bardin, Pauline Fournier, Sandra Guignard, Céline Labeyrie, Nicolas Piriou and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Silvia OghinaDepartment of Cardiology and French National Reference Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute and Clinical Investigation Centre, Hôpitaux Universitaires Henri-Mondor Assistance Publique-Hôpitaux de Paris, Créteil, France.
Damien LegalloisDepartment of Cardiology, Centre Hospitalier Universitaire de Caen-Normandie, Normandie University, Caen, France.
Fabien HyafilNuclear Medicine Department, Georges-Pompidou European Hospital, DMU IMAGINA, Assistance Publique-Hôpitaux de Paris, University of Paris Cité, Paris, France.
Walid AmaraCardiology Department, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France.
Emmanuel AndrèsInternal Medicine Department, University Hospital Strasbourg, Strasbourg, France.
Thomas BardinRheumatology Department, Institut Mutualiste Montsouris, Paris, France.
Pauline FournierCardiology Department, University Hospital Toulouse, France.
Sandra GuignardRheumatology Department, University Hospital Henri Mondor, UPEC, Créteil, France.
Céline LabeyrieDepartment of Neurology, University Hospital Bicêtre, Referral Centre for Familial Amyloid Neuropathy and other Rare Peripheral Neuropathies, Le Kremlin Bicêtre, France.
Nicolas PiriouCardiology Departement, Nantes Université, Centre Hospitalier Universitaire Nantes, l'Institut du Thorax, Nantes, France.
Olivier ToulzaCardio-Geratric Unit, University Hospital of Toulouse-Purpan, Toulouse Gerontopôle, Toulouse, France.
Romain TresorierCardiology Department, University Hospital of Clermont Ferrand, Clermont Ferrand, France.
Giorgia CanaliPfizer, Paris, France.
Margaux DuboisPfizer, Paris, France.
Benoit BouquillonCarely, Lille, France.
Cédric SauvageCarely, Lille, France.
Pierre SabouretCardiology Department, Institut de Cardiologie, Centre Hospitalier Universitaire La Pitié Salpetrière, Sorbonne Université, Paris, France.
Philippe CharronAssistance Publique-Hôpitaux de Paris, Referral Centre for Cardiac Hereditary or Rare Diseases, Cardiogen National Network Coordinator, Sorbonne University, Pitié Salpêtrière Hospital, Paris, France.
Thibaud DamyDepartment of Cardiology and French National Reference Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute and Clinical Investigation Centre, Hôpitaux Universitaires Henri-Mondor Assistance Publique-Hôpitaux de Paris, Créteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiagnosis of cardiac amyloidosis (CA) is complex and implicates several medical specialists. CA is usually suspected based on symptoms ('red flags') and non-invasive imagery. Early diagnosis and appropriate treatment are critical in patients with CA.

methodsThe DIAM-ATTR survey assessed the diagnostic pathway, from the French healthcare professional's (HCPs) perspective, for patients with transthyretin amyloidosis (ATTR)-cardiomyopathy (CM). Between February and March 2023, 13,830 HCPs were solicited to complete a 35-question survey.

resultsAmong the 13,830 HCPs solicited, 1264 HCPs completed the survey: 471 cardiologists, 186 internists, 148 nuclear medicine physicians, 125 geriatricians, 120 orthopaedic surgeons, 112 neurologists, and 102 rheumatologists. In general, echocardiographic abnormalities, heart failure, and a family history of amyloid neuropathy evoked CA. The knowledge of the 22 'red flags' assessed varied among specialists. Among HCPs, 70% had suspected an ATTR-CM: from 96% of cardiologist to 6% of orthopaedic surgeons. Complete diagnosis was performed by 48% of both cardiologists and internists. The other HCPs referred patients to colleagues for complete diagnosis. Overall, echocardiography was performed first, then gammopathy assessment and bone scintigraphy. Delays for examinations and difficulties varied among specialists.

conclusionOverall, French HCPs prioritize diagnostic examinations for ATTR-CM as recommended. However, HCPs need an increased awareness of 'red flags' and the importance of excluding monoclonal gammopathies during diagnosis.

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesEchocardiographyFemaleFranceHumansMaleMiddle AgedSurveys and Questionnairesbone scintigraphycardiac amyloidosisdiagnosisphysician’s perspectivetransthyretin amyloidosis-cardiomyopathy

Identifiers

PMID40586426
PMCPMC12210408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.